Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926289 · ClinicalTrials.gov registry record · Phase 4
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 894
- Enrollment target
NCT00926289 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 894 participants.
The verdict
NCT00926289, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 894 participants
- Enrollment target
Study Summary
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension (SBP\>=160 mmHg and Diastolic Blood Pressure(DBP)\>=100 mmHg).
Interventions
- DRUG Telmisartan
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 894 participants |
| Start Date | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926289
The ClinicalTrials.gov registry entry for NCT00926289 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 894 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Telmisartan is the first listed.
NCT00926289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00926289 about?
NCT00926289 is a clinical study titled "Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension". The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension (SBP\>=160 mmHg and Di...
What is the current status of trial NCT00926289?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 894 participants. The study started on 2009-06.
What interventions are being tested in trial NCT00926289?
The interventions under investigation include: Telmisartan (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00926289?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.